In the United States, type 2 diabetes affects 30 million people and is a major cause of morbidity and mortality.1 Glycemic control has been shown to reduce diabetes complications, particularly for microvascular disease.2,3 However, increasing recognition of adverse events due to intensive diabetes treatments has prompted major disagreements about optimal glycemic targets.
Tung EL, Davis AM, Laiteerapong N. Glycemic Control in Nonpregnant Adults With Type 2 Diabetes. JAMA. 2018;319(23):2430–2431. doi:10.1001/jama.2018.6798
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: